Anti-inflammatory Agents: Present and Future

By C. A. Dinarello. Cell, 2010

1,051 citations recorded by the source corpus.

Inflammation involving the innate and adaptive immune systems is a normal response to infection. However, when allowed to continue unchecked, inflammation may result in autoimmune or autoinflammatory disorders, neurodegenerative disease, or cancer. A variety of safe and effective anti-inflammatory agents are available, including aspirin and other nonsteroidal anti-inflammatories, with many more drugs under development. In particular, the new era of anti-inflammatory agents includes “biologicals” such as anticytokine therapies and small molecules that block the activity of kinases. Other anti-inflammatories currently in use or under development include statins, histone deacetylase inhibitors, PPAR agonists, and small RNAs. This Review discusses the current status of anti-inflammatory drug research and the development of new anti-inflammatory therapeutics.

Subfields: Immunology, Molecular Biology, Physiology

View Paper: https://www.semanticscholar.org/paper/be9fac6d04c64f1ba1268effe52f00915da643c9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Molecular Biology

In Physiology

Citations in the corpus

THE INTERLEUKIN-1 FAMILY: BACK TO THE FUTURE (2013, neutral): “IL-1 affects virtually all cells and organs and is a major pathogenic mediator of autoinflammatory, autoimmune, infectious, and degenerative diseases (Dinarello, 2009, 2010; Dinarello et al., 2012; Gabay et al., 2010; Sims and Smith, 2010) (Table 2).”
Compromised MAPK signaling in human diseases: an update (2015, background): “These findings have provided a rationale for the development of therapeutic drugs that target neuroinflammation (Dinarello 2010; Glass et al. 2010), although it remains to be determined whether chemical inhibitors of neuroinflammation are able to prevent the progression of PD or AD.”
Understanding the mechanism of IL-1β secretion (2011, background): “Although essential for resistance to infections, IL-1b also exacerbates damage during chronic disease and acute tissue injuries [76].”
Age and Age-Related Diseases: Role of Inflammation Triggers and Cytokines (2018, background): “The formulations of new and more specific drugs are likely to become available as the modes of action of kinases, such a AMPK and mTOR which control the senescence and inflammation pathways, become better understood (81, 84, 437).”